Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009

Authors

  • Audino Podda Novartis Vaccines Institute for Global Health, Siena
  • Allan James Saul Novartis Vaccines Institute for Global Health, Siena
  • Rashmi Arora Indian Council of Medical Research, New Delhi
  • Zulfiqar Bhutta Aga Khan University, Karachi
  • Anju Sinha Indian Council of Medical Research, New Delhi
  • Rajni Gaind VMMC and associated Safdarjung Hospital, New Delhi
  • Tanu Singhal Kokilaben Dhirubhai Ambani Hospital, Mumbai
  • Samir Saha Child Health Research Foundation, Shishu Hospital, Dhaka
  • Abdullah Brooks International Centre for Diarrheal Disease Reserch, Dhaka
  • Laura B. Martin Novartis Vaccines Institute for Global Health, Siena
  • Yeshwant Amdekar Jaslok Hospital and Research Center, Mumbai
  • Amar Jeet Chitkara Max Hospital, Pitampura, New Delhi
  • Mae Shieh Novartis Vaccines Institute for Global Health, Siena
  • Ambujam Nair Kapur Indian Council of Medical Research, New Delhi
  • Tulsi Das Chugh Inian Academy of Medical Sciences & BLK Memorial Hospital, New Delhi

DOI:

https://doi.org/10.3855/jidc.1048

Keywords:

enteric fever, conjugate vaccine

Abstract

Enteric fever is responsible for significant morbidity in South Asia and high prevalence of severe disease is seen in children under two years of age. Effective typhoid vaccines are available, but they cannot be used for children under two years of age and also have some limitations in older age groups. Participants supported development of a Salmonella Typhi conjugate vaccine able to induce effective, long-lasting immunity in young children. The role of Salmonella Paratyphi A as a cause of enteric fever was discussed and consensus reached that a bivalent S. Typhi-S. Paratyphi A conjugate vaccine is highly desirable; however, considering disease epidemiology and the advanced status of vaccine development, rapid introduction of monovalent S. Typhi conjugate vaccine into vaccination programs of South Asia was recommended. Prevention should be emphasized, available vaccines used, and efforts toward improving sanitation continued.

Success of the new vaccine will depend on several factors, including delivery costs and governmental ability to adopt and implement suitable immunization programs. To ensure good immunization coverage, the conjugate vaccine could be administered either to young infants, concomitantly with infant EPI vaccines, or to older infants, concomitantly with measles vaccine, currently given at 9 to 12 months. The need for new combination vaccines, containing both EPI and typhoid antigens, was discussed as a tool to increase coverage and reduce the number of injections and priority conflicts in a crowded infant vaccination schedule. However, stand-alone enteric fever conjugate vaccines would allow more flexibility to immunize different age groups and therefore should be rapidly developed.

Author Biographies

Audino Podda, Novartis Vaccines Institute for Global Health, Siena

Clinical Development & Regulatory Affairs

Allan James Saul, Novartis Vaccines Institute for Global Health, Siena

CEO

Downloads

Published

2010-05-11

How to Cite

1.
Podda A, Saul AJ, Arora R, Bhutta Z, Sinha A, Gaind R, Singhal T, Saha S, Brooks A, Martin LB, Amdekar Y, Chitkara AJ, Shieh M, Kapur AN, Chugh TD (2010) Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009. J Infect Dev Ctries 4:404–411. doi: 10.3855/jidc.1048

Issue

Section

View Points